JP2023113641A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023113641A5 JP2023113641A5 JP2023077454A JP2023077454A JP2023113641A5 JP 2023113641 A5 JP2023113641 A5 JP 2023113641A5 JP 2023077454 A JP2023077454 A JP 2023077454A JP 2023077454 A JP2023077454 A JP 2023077454A JP 2023113641 A5 JP2023113641 A5 JP 2023113641A5
- Authority
- JP
- Japan
- Prior art keywords
- methods
- new products
- manufacturing methods
- manufacturing
- methods substantially
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762564095P | 2017-09-27 | 2017-09-27 | |
| US62/564,095 | 2017-09-27 | ||
| US201762574657P | 2017-10-19 | 2017-10-19 | |
| US62/574,657 | 2017-10-19 | ||
| US201762579682P | 2017-10-31 | 2017-10-31 | |
| US62/579,682 | 2017-10-31 | ||
| US201862632812P | 2018-02-20 | 2018-02-20 | |
| US62/632,812 | 2018-02-20 | ||
| JP2020517843A JP7685833B2 (ja) | 2017-09-27 | 2018-09-26 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂによる眼疾患の治療 |
| PCT/US2018/052855 WO2019067540A1 (en) | 2017-09-27 | 2018-09-26 | TREATMENT OF OCULAR DISEASES WITH A TOTALLY HUMAN POST-TRANSLATIONAL MODIFICATION ANTI-VEGF FAB |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517843A Division JP7685833B2 (ja) | 2017-09-27 | 2018-09-26 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂによる眼疾患の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023113641A JP2023113641A (ja) | 2023-08-16 |
| JP2023113641A5 true JP2023113641A5 (enExample) | 2025-05-15 |
Family
ID=65903176
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517843A Active JP7685833B2 (ja) | 2017-09-27 | 2018-09-26 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂによる眼疾患の治療 |
| JP2023077454A Pending JP2023113641A (ja) | 2017-09-27 | 2023-05-09 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂによる眼疾患の治療 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517843A Active JP7685833B2 (ja) | 2017-09-27 | 2018-09-26 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂによる眼疾患の治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20200277364A1 (enExample) |
| EP (1) | EP3687464A4 (enExample) |
| JP (2) | JP7685833B2 (enExample) |
| KR (2) | KR20250040754A (enExample) |
| AU (2) | AU2018342094B2 (enExample) |
| CA (1) | CA3076905A1 (enExample) |
| IL (1) | IL273403A (enExample) |
| SG (1) | SG11202002396TA (enExample) |
| WO (1) | WO2019067540A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3023054T3 (en) | 2012-11-08 | 2025-05-29 | Clearside Biomedical Inc | Methods for the treatment of ocular disease in human subjects |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| WO2017180936A1 (en) | 2016-04-15 | 2017-10-19 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| MX2020006435A (es) | 2017-12-19 | 2021-02-09 | Akouos Inc | Administracion de anticuerpos terapeuticos mediada por vector de virus adenoasociado (aav) en el oido interno. |
| MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
| EP3920950A1 (en) * | 2019-02-08 | 2021-12-15 | CureVac AG | Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases |
| EP4667578A2 (en) * | 2019-04-03 | 2025-12-24 | REGENXBIO Inc. | Gene therapy for eye pathologies |
| CN110423281B (zh) * | 2019-07-31 | 2021-04-30 | 成都金唯科生物科技有限公司 | 用于治疗老年性黄斑变性的融合蛋白、病毒载体和药物 |
| MX2022002366A (es) | 2019-08-26 | 2022-07-19 | Regenxbio Inc | Tratamiento de la retinopatía diabética con fab anti-vegf completamente humano modificado postraduccionalmente. |
| KR20220081365A (ko) | 2019-10-07 | 2022-06-15 | 리젠엑스바이오 인크. | 아데노-연관 바이러스 벡터 약제학적 조성물 및 방법 |
| CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
| WO2021188803A1 (en) * | 2020-03-19 | 2021-09-23 | Clearside Biomedical, Inc. | Compositions and methods for treating ocular disorders |
| WO2022023284A1 (en) | 2020-07-27 | 2022-02-03 | Anjarium Biosciences Ag | Compositions of dna molecules, methods of making therefor, and methods of use thereof |
| CA3198368A1 (en) * | 2020-10-07 | 2022-04-14 | Regenxbio Inc. | Formulations for suprachoroidal administration such as formulations with aggregate formation |
| CR20230228A (es) | 2020-12-01 | 2023-07-18 | Akouos Inc | Construcciones de anticuerpos anti-vegf y métodos relacionados para el tratamiento de los síntomas asociados al schwannoma vestibular |
| AU2022214429A1 (en) | 2021-02-01 | 2023-09-14 | Tern Therapeutics, Llc | Gene therapy for neuronal ceroid lipofuscinoses |
| CN118019853A (zh) * | 2021-09-18 | 2024-05-10 | 九天生物医药(上海)有限公司 | 用于Wet-AMD基因治疗的AAV |
| CN116925234B (zh) * | 2022-04-02 | 2024-05-31 | 合肥星眸生物科技有限公司 | 一种编码抗vegf-a和ang-2双特异性抗体的aav载体 |
| IL319873A (en) | 2022-09-30 | 2025-05-01 | Regenxbio Inc | Treatment of eye diseases with recombinant viral vectors containing anti-VEGF FAB |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6943153B1 (en) * | 1999-03-15 | 2005-09-13 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
| US20070202186A1 (en) * | 2006-02-22 | 2007-08-30 | Iscience Interventional Corporation | Apparatus and formulations for suprachoroidal drug delivery |
| WO2010136492A2 (en) * | 2009-05-28 | 2010-12-02 | Glaxo Group Limited | Antigen-binding proteins |
| BRPI1012321A8 (pt) * | 2009-06-17 | 2016-09-27 | Abbott Biotherapeutics Corp | Anticorpos anti-vegf e seus usos |
| EP2559443A1 (en) * | 2011-08-16 | 2013-02-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of an ocular disease in a subject |
| TWI775096B (zh) * | 2012-05-15 | 2022-08-21 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| AU2014318846A1 (en) * | 2013-09-11 | 2016-03-10 | Neurotech Usa, Inc. | Encapsulated cell therapy cartridge |
| US10064752B2 (en) * | 2014-09-11 | 2018-09-04 | Orbit Biomedical Limited | Motorized suprachoroidal injection of therapeutic agent |
| JP2019501200A (ja) * | 2016-01-08 | 2019-01-17 | クリアサイド バイオメディカル，インコーポレイテッド | 後眼部障害をアフリベルセプトおよびその他の生物製剤で処置するための方法およびデバイス |
| WO2017180936A1 (en) * | 2016-04-15 | 2017-10-19 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| KR20190003556A (ko) * | 2016-04-15 | 2019-01-09 | 리젠엑스바이오 인크. | 완전히-인간형의 번역후 변형된 항-VEGF Fab를 이용한 눈 질환의 치료 |
| US20210093734A1 (en) * | 2018-02-20 | 2021-04-01 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-realted macular degeneration |
| WO2021188803A1 (en) * | 2020-03-19 | 2021-09-23 | Clearside Biomedical, Inc. | Compositions and methods for treating ocular disorders |
-
2018
- 2018-09-26 WO PCT/US2018/052855 patent/WO2019067540A1/en not_active Ceased
- 2018-09-26 JP JP2020517843A patent/JP7685833B2/ja active Active
- 2018-09-26 KR KR1020257008245A patent/KR20250040754A/ko active Pending
- 2018-09-26 KR KR1020207011989A patent/KR20200060456A/ko not_active Ceased
- 2018-09-26 SG SG11202002396TA patent/SG11202002396TA/en unknown
- 2018-09-26 EP EP18862872.1A patent/EP3687464A4/en active Pending
- 2018-09-26 CA CA3076905A patent/CA3076905A1/en active Pending
- 2018-09-26 AU AU2018342094A patent/AU2018342094B2/en active Active
- 2018-09-26 US US16/645,877 patent/US20200277364A1/en not_active Abandoned
-
2020
- 2020-03-18 IL IL273403A patent/IL273403A/en unknown
-
2023
- 2023-05-09 JP JP2023077454A patent/JP2023113641A/ja active Pending
- 2023-07-27 US US18/360,073 patent/US20240254214A1/en not_active Abandoned
-
2025
- 2025-02-26 US US19/064,049 patent/US20250320287A1/en active Pending
- 2025-05-02 AU AU2025203154A patent/AU2025203154A1/en active Pending